Intrapericardial ibutilide administration fails to terminate pacing-induced sustained atrial fibrillation in dogs

Cardiovascular Drugs and Therapy

Volumn 18, Issue 4, 2004, Pages 269-277

  Vereckei, András ^a   Gorski, J Cristopher ^b   Ujhelyi, Michael ^c   Mehra, Rahul ^c   Zipes, Douglas P ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INDIANA UNIVERSITY   (United States)

^c MEDTRONIC INC   (United States)

Author keywords

atrial fibrillation; ibutilide; intrapericardial administration

Indexed keywords

IBUTILIDE; SODIUM CHLORIDE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY SINUS; DIASTOLIC BLOOD PRESSURE; DOG; DRUG BLOOD LEVEL; EPICARDIUM; FEMALE; FEMORAL VEIN; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACEMAKER; HEART ATRIUM PACING; HEART MUSCLE POTENTIAL; HEART OUTPUT; HEART REPOLARIZATION; HEART RIGHT ATRIUM PRESSURE; HEART RIGHT VENTRICLE PRESSURE; MALE; NONHUMAN; PERICARDIUM; PRIORITY JOURNAL; QT INTERVAL; SYSTOLIC BLOOD PRESSURE;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FEMALE; HEART ATRIA; INSTILLATION, DRUG; MALE; PERICARDIUM; SULFONAMIDES; TIME FACTORS; TREATMENT FAILURE;

EID: 4544254013     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:CARD.0000041246.13952.b4     Document Type: Article

References (42)

1. Ayers GM, Rho TH, Ben-David J, Besch HR Jr, Zipes DP. Amiodarone instilled into the canine pericardial sac migrates transmurally to produce electrophysiologic effects and suppress atrial fibrillation. J Cardiovasc Electrophysiol 1996;7:713-721.
2. Spodick DH. Microphysiology of the pericardium in relation to intrapericardial therapeutics and diagnostics. Clin Cardiol 1999;22(Suppl I):I-2-I-3.
3. Verrier RL, Waxman S, Lovett EG, Moreno R. Transatrial access to the normal pericardial space. A novel approach for diagnostic sampling, pericardiocentesis and therapeutic interventions. Circulation 1998;98:2331-2333.
4. Folkman J. Angiogenic therapy of the human heart. Circulation 1998;97:628-629.
5. Landau C, Jacobs AK, Haudenshild CC. Intrapericardial basic fibroblast growth factor induces angiogenesis in a rabbit model of chronic ischemia. Am Heart J 1995;129:924-931.
6. Schumacher B, Pecher P, von Specht BU, Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: First clinical results of a new treatment of coronary heart disease. Circulation 1998;97:645-650.
7. Uchida Y, Yanigasawa-Hiwa A, Nakamura F, et al. Angiogenic therapy of acute myocardial infarction by intrapericardial injection of basic fibroblast growth factor and heparin sulfate: An experimental study. Am Heart J 1995;130:1182-1188.
8. Waltenberger J. Modulation of growth factor action: Implications for the treatment of cardiovascular diseases. Circulation 1997;96:4083-4094.
9. Ware JA, Simons M. Angiogenesis in ischemic heart disease. Nat Med 1997;3:158-164.
10. Willerson JT, Igo SR, Yao SK, Ober JC, Macris MP, Ferguson JJ. Localized administration of sodium nitroprusside enhances its protection against platelet aggregation in stenosed and injured coronary arteries. Texas Heart Inst J 1996;23:1-8.
11. Fei L, Baron AD, Henry DP, Zipes DP. Intrapericardial delivery of L-arginine reduces the increased severity of ventricular arrhythmias during sympathetic stimulation in dogs with acute coronary occlusion: Nitric oxide modulates sympathetic effects on ventricular electrophysiological properties. Circulation 1997;96:4044-4049.
12. Avitall B, Hare J, Zander G, et al. Iontophoretic transmyocardial drug delivery: A novel approach to antiarrhythmic drug therapy. Circulation 1992;85:1582-1593.
13. Miyazaki T, Zipes DP. Pericardial prostaglandin biosynthesis prevents the increased incidence of reperfusion-induced ventricular fibrillation produced by efferent sympathetic stimulation in dogs. Circulation 1990;82:1008-1019.
14. Ujhelyi MR, Hadsall KZ, Euler DE, Mehra R. Intrapericardial therapeutics: A pharmacodynamic and pharmacokinetic comparison between pericardial and intravenous procainamide delivery. J Cardiovasc Electrophysiol 2002;13:605-611.
15. Aoki M, Morishita R, Muraishi A, et al. Efficient in vivo gene transfer into the heart in the rat myocardial infarction model using the HVJ (hemagglutinating virus of Japan)-liposome method. J Mol Cell Cardiol 1997;29:949-959.
16. Lamping ICG, Rios CD, Chun JA, Ooboshi H, Davidson BL, Heistad DD. Intrapericardial administration of adenovirus for gene transfer. Am J Physiol 1997;272:H310-H317.
17. Lewis BS, Flugelman MY, Weisz A, Keren-Tal I, Schaper W. Angiogenesis by gene therapy: A new horizon for myocardial revascularization? Cardiovasc Res 1997;35:490-497.
18. Laham RJ, Simons M, Hung D. Subxyphoid access to the normal pericardium: A novel drug delivery technique. Catheterization and Cardiovascular Interventions 1999;47:109-111.
19. Macris MP, Igo SR. Minimally invasive access of the normal pericardium: initial clinical experience with a novel device. Clin Cardiol 1999;22(1 Suppl 1):136-139.
20. Chugh SS, Johnson SB, Packer DL. Altered response to ibutilide in a heart failure model. Cardiovasc Res 2001;49:94-102.
21. Wood MA, Stambler BS, Ellenbogen KA, et al. Suppression of inducible ventricular tachycardia by ibutilide in patients with coronary artery disease. Ibutilide investigators. Am Heart J 1998;135:1048-1054.
22. Buchanan LV, Kabell G, Turcotte UM, Brunden MN, Gibson JK. Effects of ibutilide on spontaneous and induced ventricular arrhythmias in 24-hour canine myocardial infarction: A comparative study with sotalol and encainide. J Cardiovasc Pharmacol 1992;19:256-263.
23. Chen YJ, Hsieh MH, Chiou CW, Chen SA. Electropharmacologic characteristics of ventricular proarrhythmia induced by ibutilide. J Cardiovasc Pharmacol 1999;34:237-247.
24. Stambler BS, Wood MA, Ellenbogen KA. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation. Electrophysiological determinants of enhanced conversion efficacy. Circulation 1997;96:4298-4306.
25. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, Vanderlught JT and the Ibutilide Repeat Dose Study Investigators. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996;94:1613-1621.
26. Vereckei A, Warman E, Mehra R, Zipes DP. Comparison of the effects on drug concentrations, electrophysiologic parameters, and termination of atrial fibrillation in dogs, when procainamide and ibutilide are delivered into the right atrium versus intravenously. J Cardiovasc Electrophysiol 2001;12:330-336.
27. Labhasetwar V, Underwood T, Hek RW, Gallagher M, Langberg J, Levy RJ. Epicardial administration of ibutilide from polyurethane matrices: Effects on de fibrillation threshold and electrophysiologic parameters. J Cardiovasc Pharmacol 1994;24:826-840.
28. Li D, Benardeau A, Nattel S. Contrasting efficacy of dofetilide in differing experimental models of atrial fibrillation. Circulation 2000;102:104-112.
29. Shinagawa K, Shiroshita-Takeshita A, Schram G, Nattel S. Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium. Insights into the mechanism of the superior efficacy of amiodarone. Circulation 2003;107:1440-1446.
30. Tse HF, Lau CP. Electrophysiologic actions of dl-sotalol in patients with persistent atrial fibrillation. J Am Coll Cardiol 2002;40:2150-2155.
31. Wang J, Feng J, Nattel S. Class III antiarrhythmic drug action in experimental atrial fibrillation: differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide. Circulation 1994;90:2032-2040.
32. Cha Y, Wales A, Wolf P, Shahrokni S, Sawhney N, Feld GK. Electrophysiologic effects of the new class III antiarrhythmic drug dofetilide compared to the class IA antiarrhythmic drug quinidine in experimental canine atrial flutter: Role of dispersion of refractoriness in antiarrhythmic efficacy. J Cardiovasc Electrophysiol 1996;7:809-827.
33. Falk RH, Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation and flutter. Intravenous Dofetilide Investigators. J Am Coll Cardiol 1997;29:385-390.
34. Norgaard BL, Wachtell K, Christensen PD, et al. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Am Heart J 1999;137:1062-1069.
35. Buchanan LV, Le Hay RJ, Walters RR, Hsu CY, Brunden MN, Gibson JK. Antiarrhythmic and electrophysiologic effects of intravenous ibutilide and sotalol in the canine sterile pericarditis model. J Cardiovasc Electrophysiol 1996;7:113-119.
36. Buchanan LV, Turcotte UM, Kabell GG, Gibson JR. Antiarrhythmic and electrophysiologic effects of ibutilide in a chronic canine model of atrial flutter. J Cardiovasc Pharmacol 1993;22:10-4.
37. Morillo CA, Klein GJ, Jones DL, Guiraudon CM. Chronic rapid atrial pacing. Structural, functional and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation 1995;91:1588-1595.
38. Elvan A, Wylie K, Zipes DP. Pacing-induced chronic atrial fibrillation impairs sinus node function in dogs. Electrophysiological remodeling. Circulation 1996;94:2953-2960.
39. Chang C-M, Wu T-J, Zhou S, et al. Nerve sprouting and sympathetic hyperinnervation in a canine model of atrial fibrillation produced by prolonged right atrial pacing. Circulation 2001;103:22-25.
40. Labhasetwar V, Strickberger SA, Underwood T, Davis J, Levy RJ. Prevention of acute inducible atrial flutter in dogs by using an ibutilide-polymer-coated pacing electrode. J Cardiovasc Pharmacol 1998;31:449-455.
41. Nabih MA, Prcevski P, Fromm BS, et al. Effect of ibutilide, a new class III agent on sustained atrial fibrillation in a canine model of acute ischemia and myocardial dysfunction induced by microembolization. Pacing Clin Electrophysiol 1993;16:1975-1983.
42. Khoury DS, Assar MD, Sun H. Pharmacologic enhancement of atrial electrical defibrillation efficacy: Role of ibutilide. J Interv Card Electrophysiol 1997;1:291-298.